This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ilson, D. H. Articles by Kelsen, D. P. Search for Related Content PubMed PubMed Citation Articles by Ilson, D. H. Articles by Kelsen, D. P. Social Bookmarking                            What's this?

Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer

From the Gastrointestinal Oncology Service, Departments of Medicine, Biostatistics, and Psychiatry, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to David H. Ilson, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email ilsond{at}mskcc.org

PURPOSE: To evaluate the response, toxicity, survival, and quality of life in patients with unresectable or metastatic esophageal cancer treated with weekly irinotecan and cisplatin.

PATIENTS AND METHODS: Thirty-five patients with metastatic or unresectable esophageal adenocarcinoma (23 patients) or squamous cell carcinoma (12 patients) were treated. No prior chemotherapy was allowed. The majority of patients had metastatic and bidimensionally measurable disease (34 patients each [97%]). Patients were treated with cisplatin 30 mg/m² and irinotecan 65 mg/m², repeated weekly for 4 weeks, followed by a 2-week rest period. Treatment was recycled every 6 weeks. Degree of dysphagia relief was monitored, and quality of life was measured prospectively using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 and Functional Assessment of Cancer Therapy–General instruments.

RESULTS: Thirty-five patients were assessable for response and toxicity. Major objective responses were observed in 20 patients (57%; 95% confidence interval, 41% to 73%), including two complete responses (6%). Similar response rates were observed for adenocarcinoma (12 of 23 patients; 52%) and squamous carcinoma (eight of 12 patients; 66%). The median duration of response was 4.2 months (range, 1 to 8.8+ months). Median actuarial survival was 14.6 months (range, 1 to 15.2+ months). In 20 patients with dysphagia assessable at baseline, 18 (90%) noted either improvement or resolution of dysphagia on chemotherapy. Global quality of life improved in responding patients, primarily because of improvements in pain, emotional state, and relationships with family and friends. Toxicity was relatively mild and included only three patients (9%) with grade 4 neutropenia and four (11%) with grade 3 diarrhea. There were no treatment-related deaths.

CONCLUSION: The combination of weekly cisplatin plus irinotecan had significant activity in metastatic esophageal carcinoma and resulted in significant relief of dysphagia. The regimen was well tolerated, with acceptable myelosuppression and rare treatment-related diarrhea. Further evaluation of the combination of weekly irinotecan and cisplatin, including the addition of other agents to this regimen, is indicated.

Presented at the Thirty-Fourth Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 15-19, 1998.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D.G. Power and D.H. Ilson Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 145 - 165. [Abstract] [PDF]

				S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie Ann. Onc., October 1, 2009; 20(10): 1667 - 1673. [Abstract] [Full Text] [PDF]

				W. Cao, C. Xu, G. Lou, J. Jiang, S. Zhao, M. Geng, W. Xi, H. Li, and Y. Jin A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 582 - 587. [Abstract] [Full Text] [PDF]

				B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer Ann. Onc., July 1, 2009; 20(7): 1242 - 1248. [Abstract] [Full Text] [PDF]

				P. C. Enzinger, D. P. Ryan, J. W. Clark, A. Muzikansky, C. C. Earle, M. H. Kulke, J. A. Meyerhardt, L. S. Blaszkowsky, A. X. Zhu, P. Fidias, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer Ann. Onc., March 1, 2009; 20(3): 475 - 480. [Abstract] [Full Text] [PDF]

				M. J. Desai, A. Kim, P. C. Fall, and D. Wang Optimizing Quality of Life Through Palliative Care J Am Osteopath Assoc, December 1, 2007; 107(suppl_7): ES9 - ES14. [Abstract] [Full Text] [PDF]

				M. A. Shah, R. K. Ramanathan, D. H. Ilson, A. Levnor, D. D'Adamo, E. O'Reilly, A. Tse, R. Trocola, L. Schwartz, M. Capanu, et al. Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma J. Clin. Oncol., November 20, 2006; 24(33): 5201 - 5206. [Abstract] [Full Text] [PDF]

				I. E.L.M. Kuppens, E. Dansin, H. Boot, C. Feger, S. Assadourian, M.-E. Bonneterre, J. H. Beijnen, J. H.M. Schellens, and J. Bonneterre Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin. Cancer Res., June 15, 2006; 12(12): 3774 - 3781. [Abstract] [Full Text] [PDF]

				A. Kim, P. Fall, and D. Wang Palliative Care: Optimizing Quality of Life J Am Osteopath Assoc, November 1, 2005; 105(suppl_5): S9 - S14. [Abstract] [Full Text] [PDF]

				W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF]

				A. M. Mauer, E. H. Kraut, S. A. Krauss, R. H. Ansari, K. Kasza, L. Szeto, E. E. Vokes, and for the University of Chicago Phase II Network Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus Ann. Onc., August 1, 2005; 16(8): 1320 - 1325. [Abstract] [Full Text] [PDF]

				I. Chau, A. R. Norman, D. Cunningham, J. S. Waters, J. Oates, and P. J. Ross Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer--Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data J. Clin. Oncol., June 15, 2004; 22(12): 2395 - 2403. [Abstract] [Full Text] [PDF]

				K. Muro, T. Hamaguchi, A. Ohtsu, N. Boku, K. Chin, I. Hyodo, H. Fujita, W. Takiyama, and T. Ohtsu A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann. Onc., June 1, 2004; 15(6): 955 - 959. [Abstract] [Full Text] [PDF]

				M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Oncologist, April 1, 2004; 9(2): 147 - 159. [Abstract] [Full Text] [PDF]

				M. B. Polee, A. Sparreboom, F. A. L. M. Eskens, R. Hoekstra, J. van de Schaaf, J. Verweij, G. Stoter, and A. van der Gaast A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer Clin. Cancer Res., March 15, 2004; 10(6): 1928 - 1934. [Abstract] [Full Text] [PDF]

				J. R. Kroep, H. M. Pinedo, G. Giaccone, A. Van Bochove, G. J. Peters, and C. J. Van Groeningen Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer Ann. Onc., February 1, 2004; 15(2): 230 - 235. [Abstract] [Full Text] [PDF]

				L. Assersohn, G. Brown, D. Cunningham, C. Ward, J. Oates, J. S. Waters, M. E. Hill, and A. R. Norman Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann. Onc., January 1, 2004; 15(1): 64 - 69. [Abstract] [Full Text] [PDF]

				P. C. Enzinger and R. J. Mayer Esophageal Cancer N. Engl. J. Med., December 4, 2003; 349(23): 2241 - 2252. [Full Text] [PDF]

				J. S. Macdonald Chemotherapy in the Management of Gastric Cancer J. Clin. Oncol., December 1, 2003; 21(90230): 276s - 279. [Full Text] [PDF]

				D. H. Ilson, M. Bains, D. P. Kelsen, E. O'Reilly, M. Karpeh, D. Coit, V. Rusch, M. Gonen, K. Wilson, and B. D. Minsky Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer J. Clin. Oncol., August 1, 2003; 21(15): 2926 - 2932. [Abstract] [Full Text] [PDF]

				Y. Xu and M. A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Onc., December 1, 2002; 13(12): 1841 - 1851. [Abstract] [Full Text] [PDF]

				T. Conroy, P.-L. Etienne, A. Adenis, M. Ducreux, B. Paillot, J. Oliveira, J.-F. Seitz, E. Francois, E. Van Cutsem, D. J. T. Wagener, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival Ann. Onc., May 1, 2002; 13(5): 721 - 729. [Abstract] [Full Text] [PDF]

				M. L. Rothenberg Irinotecan (CPT-11): Recent Developments and Future Directions-Colorectal Cancer and Beyond Oncologist, February 1, 2001; 6(1): 66 - 80. [Abstract] [Full Text]